Traws Pharma ( (TRAW) ) has shared an announcement.
Traws Pharma announced on February 28, 2025, that it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, ensuring continued listing on the Nasdaq Capital Market. This follows a successful hearing and a $20 million financing, positioning Traws to advance its antiviral programs, particularly for bird flu and influenza, while being subject to a one-year monitoring period to maintain compliance.
More about Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for respiratory viral diseases. Their pipeline includes drug candidates for bird/pandemic flu and COVID-19, with a commitment to addressing unmet medical needs through advanced drug development technology.
YTD Price Performance: -61.25%
Average Trading Volume: 584,877
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.27M
See more data about TRAW stock on TipRanks’ Stock Analysis page.